Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Lee, Michael S, Ryoo, Baek-Yeol, Hsu, Chih-Hung, Numata, Kazushi, Stein, Stacey, Verret, Wendy, Hack, Stephen P, Spahn, Jessica, Liu, Bo, Abdullah, Heba, Wang, Yulei, He, Aiwu Ruth, Lee, Kyung-Hun, Bang, Y-J, Bendell, J, Chao, Y, Chen, J-S, Chung, H C, Davis, S L, Dev, A, Gane, E, George, B, He, A R, Hochster, H, Hsu, C-H, Ikeda, M, Lee, J, Lee, M, Mahipal, A, Manji, G, Morimoto, M, Numata, K, Pishvaian, M, Qin, S, Ryan, D, Ryoo, B-Y, Sasahira, N, Stein, S, Strickler, J, Tebbutt, N
Published in The lancet oncology (01.06.2020)
Published in The lancet oncology (01.06.2020)
Get full text
Journal Article
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
Hellmann, M.D., Kim, T.-W., Lee, C.B., Goh, B.-C., Miller, W.H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L.Q.M., Gainor, J.F., Desai, J., Solomon, B.J., Das Thakur, M., Pitcher, B., Foster, P., Hernandez, G., Wongchenko, M.J., Cha, E., Bang, Y.-J., Siu, L.L., Bendell, J.
Published in Annals of oncology (01.07.2019)
Published in Annals of oncology (01.07.2019)
Get full text
Journal Article
Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)
Cohen, R., Shi, Q., Meyers, J., Jin, Z., Svrcek, M., Fuchs, C., Couture, F., Kuebler, P., Ciombor, K.K., Bendell, J., De Jesus-Acosta, A., Kumar, P., Lewis, D., Tan, B., Bertagnolli, M.M., Philip, P., Blanke, C., O'Reilly, E.M., Shields, A., Meyerhardt, J.A.
Published in Annals of oncology (01.10.2021)
Published in Annals of oncology (01.10.2021)
Get full text
Journal Article
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
Yoon, H.H., Bendell, J.C., Braiteh, F.S., Firdaus, I., Philip, P.A., Cohn, A.L., Lewis, N., Anderson, D.M., Arrowsmith, E., Schwartz, J.D., Gao, L., Hsu, Y., Xu, Y., Ferry, D., Alberts, S.R., Wainberg, Z.A.
Published in Annals of oncology (01.12.2016)
Published in Annals of oncology (01.12.2016)
Get full text
Journal Article
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
Bendell, J., O'Reilly, E.M., Middleton, M.R., Chau, I., Hochster, H., Fielding, A., Burke, W., Burris, H.
Published in Annals of oncology (01.04.2015)
Published in Annals of oncology (01.04.2015)
Get full text
Journal Article
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
Tolcher, A.W., Bendell, J.C., Papadopoulos, K.P., Burris, H.A., Patnaik, A., Jones, S.F., Rasco, D., Cox, D.S., Durante, M., Bellew, K.M., Park, J., Le, N.T., Infante, J.R.
Published in Annals of oncology (01.01.2015)
Published in Annals of oncology (01.01.2015)
Get full text
Journal Article
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)
Kundranda, M., Gracian, A.C., Zafar, S.F., Meiri, E., Bendell, J., Algül, H., Rivera, F., Ahn, E.R., Watkins, D., Pelzer, U., Charu, V., Zalutskaya, A., Kuesters, G., Pipas, J.M., Santillana, S., Askoxylakis, V., Ko, A.H.
Published in Annals of oncology (01.01.2020)
Published in Annals of oncology (01.01.2020)
Get full text
Journal Article
Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors
Isakoff, S.J., Tabernero, J., Molife, L.R., Soria, J.-C., Cervantes, A., Vogelzang, N.J., Patel, M.R., Hussain, M., Baron, A., Argilés, G., Conkling, P.R., Sampath, D., Maslyar, D., Patel, P., Chan, W., Gendreau, S., Musib, L., Xu, N., Ma, H., Lin, K., Bendell, J.
Published in Annals of oncology (01.05.2020)
Published in Annals of oncology (01.05.2020)
Get full text
Journal Article
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
Pant, S., Saleh, M., Bendell, J., Infante, J.R., Jones, S., Kurkjian, C.D., Moore, K.M., Kazakin, J., Abbadessa, G., Wang, Y., Chen, Y., Schwartz, B., Camacho, L.H.
Published in Annals of oncology (01.07.2014)
Published in Annals of oncology (01.07.2014)
Get full text
Journal Article
Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer
Bendell, J., Ciardiello, F., Tabernero, J., Tebbutt, N., Eng, C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N., Sobrero, A., Shi, Y., Roberts, L., Yan, Y., Chang, I., Uyei, A., Kim, T.
Published in Annals of oncology (01.06.2018)
Published in Annals of oncology (01.06.2018)
Get full text
Journal Article
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
Grilley-Olson, J. E., Bedard, P. L., Fasolo, A., Cornfeld, M., Cartee, L., Razak, A. R. Abdul, Stayner, L.-A., Wu, Y., Greenwood, R., Singh, R., Lee, C. B., Bendell, J., Burris, H. A., Del Conte, G., Sessa, C., Infante, J. R.
Published in Investigational new drugs (01.12.2016)
Published in Investigational new drugs (01.12.2016)
Get full text
Journal Article
A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy
Ciardiello, F., Bang, Y.-J., Bendell, J., Cervantes, A., Brachmann, R., Zhang, K., Raponi, M., Farin, H., Shen, L.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy - Trial in progress
Ciardiello, F., Bang, Y., Bendell, J., Cervantes, A., Brachmann, R., Zhang, Y., Raponi, M., Farin, H., Shen, L.
Published in Annals of oncology (01.06.2018)
Published in Annals of oncology (01.06.2018)
Get full text
Journal Article
Corrigendum to ‘Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)’: Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79–87
Kundranda, M., Gracian, A.C., Zafar, S.F., Meiri, E., Bendell, J., Algül, H., Rivera, F., Ahn, E.R., Watkins, D., Pelzer, U., Charu, V., Zalutskaya, A., Kuesters, G., Pipas, J.M., Santillana, S., Askoxylakis, V., Ko, A.H.
Published in Annals of oncology (01.08.2020)
Published in Annals of oncology (01.08.2020)
Get full text
Journal Article
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer
Finn, R. S., Ahn, D. H., Javle, M. M., Tan, B. R., Weekes, C. D., Bendell, J. C., Patnaik, A., Khan, G. N., Laheru, D., Chavira, R., Christy-Bittel, J., Barrett, E., Sawyer, M. B., Bekaii-Saab, Tanios S.
Published in Investigational new drugs (01.12.2018)
Published in Investigational new drugs (01.12.2018)
Get full text
Journal Article
Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)
Chau, I., Bendell, J., Soriano, A., Arkenau, H., Cultrera, J., Santana-Davila, R., Calvo, E., Tourneau, C. Le, Zender, L., Mi, G., Schelman, W., Ferry, D., Herbst, R., Fuchs, C.
Published in Annals of oncology (01.07.2019)
Published in Annals of oncology (01.07.2019)
Get full text
Journal Article
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy
Moore, M., Gill, S., Asmis, T., Berry, S., Burkes, R., Zbuk, K., Alcindor, T., Jeyakumar, A., Chan, T., Rao, S., Spratlin, J., Tang, P.A., Rothenstein, J., Chan, E., Bendell, J., Kudrik, F., Kauh, J., Tang, S., Gao, L., Kambhampati, S.R.P., Nasroulah, F., Yang, L., Ramdas, N., Binder, P., Strevel, E.
Published in Annals of oncology (01.12.2016)
Published in Annals of oncology (01.12.2016)
Get full text
Journal Article
Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies
Klempner, S.J., Bendell, J., Meucci Villaflor, V., Tenner, L., Stein, S., Sirard, C.A., Newman, W., Kagey, M., Schlienger, K., Strickler, J.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer
Rustin, G., Vergote, I., Micha, J.P., Duska, L.R., Reed, N., Bendell, J., Spitz, D., Dark, G., Hoch, U., Tagliaferri, M., Hannah, A.L., Garcia, A.A.
Published in Gynecologic oncology (01.11.2017)
Published in Gynecologic oncology (01.11.2017)
Get full text
Journal Article